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Glutamine synthetase (GS) is the enzyme responsible for the biosynthesis of glutamine, 
providing the only source of endogenous glutamine necessary for several critical 
metabolic and developmental pathways. Glutamine synthetase (GS) deficiency, caused 
by pathogenic variants in the glutamate-ammonia ligase (GLUL) gene, is a rare 
autosomal recessive inborn error of metabolism characterized by systemic glutamine 
deficiency, persistent moderate hyperammonemia, and clinically devastating seizures and 
multi-organ failure shortly after birth. The four cases reported thus far were caused by 
homozygous GLUL missense variants. We report a case of GS deficiency caused by 
homozygous GLUL gene deletion, diagnosed prenatally and likely representing the most 
severe end of the spectrum. We expand the known phenotype of this rare condition with 
novel dysmorphic, radiographic and neuropathologic features identified on post-mortem 
examination. The biallelic deletion identified in this case also included the RNASEL gene 
and was associated with immune dysfunction in the fetus. This case demonstrates that 
total absence of the GLUL gene in humans is viable beyond the embryonic period, 
despite the early embryonic lethality found in GLUL animal models.  
 
Keywords: Glutamine synthetase; GLUL; 1q25.3 deletion 
Running Title: Homozygous GLUL deletion causes glutamine synthetase deficiency 
 
Introduction 
Glutamine synthetase (GS) is the enzyme responsible for the biosynthesis of glutamine 
from glutamate and ammonia, providing the only source of endogenous glutamine 
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necessary for several essential developmental and metabolic pathways, including cellular 
signalling and proliferation, neurotransmitter and nucleic acid production, acid-base 
homeostasis, nitrogen metabolism and ammonia detoxification (1-3). GS deficiency 
(OMIM #610015), caused by pathogenic variants in the glutamate-ammonia ligase 
(GLUL) gene, is a rare autosomal recessive inborn error of metabolism characterized by 
systemic glutamine deficiency and persistent moderate hyperammonemia (4). Four cases 
of GS deficiency have been reported thus far (Table 1) (4-8); two presented during the 
neonatal period with severe encephalopathy, brain malformations and subsequent multi-
organ failure and death in infancy, while the third presented with intractable seizures at 2 
weeks of age and eventually died at six years of age (6). The fourth case presented at 5 
months of age with seizures and developmental delay, and is still living (7). All four 
cases had consanguineous parents and were found to have homozygous missense variants 
in the GLUL gene (4-8). Because of the wide array of biological roles requiring 
glutamine and the early embryonic lethality in GLUL animal models (1,9,10), total 
absence of GS function in utero was thought to be embryonically lethal in humans (1). 
We report a case of GS deficiency caused by homozygous deletion of the entire GLUL 
gene. This case is also the first to exhibit a homozygous RNASEL gene deletion; while 
RNASEL mouse studies reveal a role for this gene in immune development (11), biallelic 
RNASEL deletion in humans is of unknown clinical significance. We describe the 
immune phenotype in the current case and suggest T cell immunodeficiency as a possible 





A 28-year-old woman of Czech descent was evaluated in the Prenatal Genetics clinic for 
intrauterine fetal growth restriction at 15+5 weeks gestation. This in vitro fertilization-
assisted, dizygotic dichorionic diamniotic twin pregnancy was initially uncomplicated. 
The woman and her partner are second cousins and had a history of male factor 
infertility. Family history was otherwise non-contributory. 
 
At 15+5 weeks gestation, ultrasound revealed hydrops fetalis and intrauterine fetal 
demise in one twin and symmetrical growth restriction in the remaining live twin. Further 
ultrasounds at 17+5 weeks and 18+6 weeks gestation revealed normal anatomy in the live 
fetus, with persistent symmetric growth restriction. There was no evidence of placental 
dysfunction. At 22 and 27 weeks gestation, respectively, fetal ultrasound and brain MRI 
revealed microcephaly, smooth cortical mantel with delayed gyral formation, 
parenchymal signal changes, especially in the temporal lobes, severe vermian and 
cerebellar hypoplasia, thin brainstem with hypoplastic pons, and hypoplastic corpus 
callosum (Figure 1).  
 
Amniocentesis was performed and microarray analysis identified a 543.6Kb homozygous 
1q25.3 deletion (arr[GRCh37] 1q25.3(182058556_182601111)x0) resulting in the loss of 
both copies of the GLUL and RNASEL OMIM morbid genes and 6 RefSeq genes 
(RGSL1, RGS16, LOC284648, JA429801, JA429802, LINC00272). Parents were found to 
be heterozygous carriers of the deletion. The couple was counselled and opted for 




Pathological findings   
Post-mortem examination revealed a female infant at 29 weeks gestation with overall 
small growth parameters for gestational age (Table 1). There was a sloping forehead, 
hypertelorism, broad nasal bridge, bulging eyes, large tongue, thickened nuchal skin, 
bilateral talipes equinovarus, 2nd toe overlapping the first toe bilaterally, left 5th toe 
overlapping the 4th toe, and left 4th toe overlapping the 3rd toe (Figure 2). There was an 
ostium secundum atrial septal defect. The lungs were bilobed bilaterally. There was a 
persistent omphalomesenteric duct. Neuropathologic evaluation revealed 
microencephaly, delayed sulcation and cortical development, widespread neuronal 
hypoplasia, areas of abnormal cortical maturation, scattered white matter calcifications, 
premature germinal matrix depletion, dentate-olivary dysplasia and spinal cord 
hypoplasia (Figure 2). Myelination was mildly delayed. Radiologic images showed 
prominent coronal clefting and mild sagittal notching of the vertebral bodies, 13 pairs of 
ribs, disproportionate shortening of the upper and lower limbs compared to the trunk and 
hands, and small inferior iliac medial and lateral spurs (Figure 2). The placenta was small 
(<10th centile for age). Fibroblasts were obtained as a secondary source of fetal sample 
for genetic and metabolic testing but the cells failed to grow when cultured.  
 
Biochemical results  
Prior to termination of pregnancy, fetal blood was collected for amino acid quantification 
and revealed a very low concentration of glutamine (92 µM; neonatal reference interval 
(RI) 451-1,113 µM). Maternal plasma glutamine concentration was borderline low 
normal (379 µM; adult RI: 397-781 µM). Fetal and maternal glutamate concentrations 
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were normal, 83 µM (RI: 91-401 µM) and 43 µM (RI: 15-112 µM) respectively, 
indicating that low glutamine content was not secondary to poor specimen handling. 
 
Immune phenotype 
Bone marrow sample showed trilineage hematopoiesis. The thymus weight was 
borderline small at 1.95g (expected mean and SD for 29 weeks gestation is 3.44 +/- 1.49 
g). Flow cytometry and immunohistochemistry of subpopulations in the thymus revealed 
CD3+CD4-CD8- cells, indicating that only very early thymocytes were detected. 
 
Discussion:  
Glutamine synthetase (GS) deficiency was initially characterized by neonatal epileptic 
encephalopathy and death from multi-organ failure in the first days to weeks of life (4). 
Biochemically, it is defined by decreased levels of glutamine in blood, urine and 
cerebrospinal fluid and chronic moderate hyperammonemia (4). Other common clinical 
findings are microcephaly, brain atrophy and structural brain malformations (4-6,8). The 
most recently described case appears to have the mildest phenotype and is the only case 
still living (7).  
 
In the current case, the presence of dysmorphic features and cardiac, lung and skeletal 
defects broadens the known clinical phenotype of GS deficiency. Interestingly, 
intrauterine growth restriction was the presenting feature; growth restriction and 
micromelia have been described in two other cases of GS deficiency (3), suggesting a 
role for the GLUL gene in fetal growth and/or skeletal development. The most striking 
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neuropathological finding was the global hypoplasia affecting the brain, brainstem and 
spinal cord (Figure 2). This underscores the vital importance of glutamine in brain 
development.  
 
Complete absence of the GLUL gene was previously shown to be embryonically lethal in 
animal models (1,9,10) and has not been reported in humans until now. In the prenatal 
period, glutamine is needed for cell proliferation, blastocyst implantation, brain 
development and overall survival (reviewed in 3), suggesting that absence of the GLUL 
gene should not be viable. Our case supports viability of homozygous GLUL deletion at 
least beyond the early embryonic period. It should be noted that the hydrops and fetal 
demise of the case’s co-twin may be a more severe manifestation of homozygous GLUL 
deletion. Viability (until the time of interruption of pregnancy at 29 weeks gestation) in 
the remaining twin may have resulted from maternal glutamine released by the placenta; 
indeed, the mother’s glutamine levels were consistent with partial enzyme production and 
the fetus was found to have low (92 µM), but not undetectable, levels of glutamine in her 
blood. Unique to this case is the fact that fetal glutamine was present presumably 
exclusively from maternal and/or placental synthesis as opposed to GLUL upregulation 
which was described in the other known cases (4-6,8), but would not be possible with a 
homozygous GLUL gene deletion. Our case supports previous reports of fibroblast 
growth failure in GS deficiency, further indicating the imperative role glutamine plays in 
cell survival (12).  
 
RNASEL gene deletion  
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RNASEL encodes RNase L, an interferon-regulated RNA degradation enzyme which 
controls viral and cellular growth (11). Heterozygous and homozygous missense variants 
in RNASEL have been associated with decreased, but not absent, RNase L activity and 
have been linked to cancer susceptibility in humans (13,14). Immune studies on the 
current case showed a predominance of CD3+CD4-CD8- cells in the thymus, suggestive 
of a T cell immunodeficiency. The RNASEL deficient mouse appears to be susceptible to 
infections and has a defect in thymocyte apoptosis (11), which is inconsistent with our 
findings. This could be due to species-specific diversity or that the findings in the 
immune system of the current case result from a combined effect of deficiency in 
RNASEL and one or more of the other genes in the deletion.  
 
As with all copy number variations affecting more than one gene, it is difficult to 
distinguish how each gene involved contributes to the overall phenotype. A review of the 
6 RefSeq genes (RGSL1, RGS16, LOC284648, JA429801, JA429802, LINC00272) 
affected by the deletion in addition to GLUL and RNASEL, and the areas of 
homozygosity apparent on the microarray, did not identify genes that would better 
explain the current case’s phenotype. Therefore, we propose that biallelic loss of 
RNASEL function may be a novel cause of T cell immunodeficiency. Alternatively, 
because glutamine is utilized in T lymphocyte activation (15), immune dysfunction may 
be an unrecognized feature of GS deficiency and immunological testing may be 
warranted in these cases. Further studies on the immune function in GS deficiency 
patients and the role of RNASEL in immune development are needed to clarify this 
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association. Until then, we propose that children diagnosed with GS deficiency undergo 
immune evaluation to identify potentially treatable deficiencies. 
 
Here, we present a case of GS deficiency caused by total absence of the GLUL gene, 
likely representing the most severe end of the spectrum. The novel findings presented 
here should prompt investigations for cardiac, lung and skeletal malformations in current 
and future cases of GS deficiency. Maternal supply of glutamine appears to support fetal 
viability in the context of homozygous GLUL deletion in the fetus. Further studies are 
needed to identify whether glutamine supplementation in carrier mothers may ameliorate 
or even prevent the severe multisystemic sequelae of this rare condition. 
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Figure 1: Fetal imaging studies in a case of homozygous 1q25.3 deletion. 
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Ultrasound images (top) revealed short femur (A) at 22 weeks gestation, cerebellar 
hypoplasia (arrow), delayed gyral formation and absent cavum septum pellucidum (*) at 
22 weeks (B) and 26 weeks (C,D) gestation.  
Fetal MRI at 27 weeks’ gestation (bottom): Single shot fast spin echo (SSFSE) images 
reveal severely hypoplastic corpus callosum (G; short arrow), thin brainstem with 
hypoplastic pons (G; arrow) vermian hypoplasia and multiple periventricular cavitations 
(E; arrow), severely hypoplastic cerebellum (arrow), and marked simplification of 
cortical gyral development (arrow) (H). 
 
Figure 2: Post-mortem findings in a case of homozygous 1q25.3 deletion. 
Radiographic images show upper and lower limbs disproportionately short compared to 
trunk and hands (A), prominent coronal clefting (white arrow), sagittal notching (black 
arrow) of vertebral bodies (B), small inferior iliac medial and lateral spurs (C). 
Gross pathological examination revealed microencephaly with delayed sulcation and 
cortical development (D) compared to typical brain at same gestational age (E) and facial 
dysmorphisms (F). Coronal view of brain anatomy (G) showed overall preservation of 
general architecture with extreme atrophy and premature germinal matrix depletion, 
hypoplastic corpus callosum with irregular aspect anteriorly (*), subependymal zone 
rarified with germinolysis (arrow). Histopathology demonstrating overall cortical 
architecture preserved (H), prominent laminar arrangement with excess of microlaminar 
within the developing cortical laminae (I).  
 
 
